Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock
Authors:
- Vinu Balraam KvVKVinu Balraam Kv
- Amiya R. NayakANAmiya R. Nayak
- Jasmita DassJDJasmita Dass
- Richa ChauhanRCRicha Chauhan
- Ganesh K. ViswanathanGVGanesh K. Viswanathan
- Mukul AggarwalMAMukul Aggarwal
- Pradeep KumarPKPradeep Kumar
- Rishi DhawanRDRishi Dhawan
- Tulika SethTSTulika Seth
- Manoranjan MahapatraMMManoranjan Mahapatra
- 26 June 2026
- journal article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (6) , 283-286
Abstract
Background: Systemic mastocytosis (SM) with associated acute myeloid leukemia (AML) is a rare malignancy usually linked to KIT p.D816V mutations. Observation(s): We report a 17-year-old female with RUNX1::RUNX1T1 -positive AML and florid mast cell proliferation harboring a rare KIT exon 8 deletion (p.Asp419del). Diagnosis required integration of morphology, immunophenotyping, and polymerase chain reaction, as routine NGS failed to detect the mutation. Despite remission following intensive chemotherapy and imatinib, the patient developed persistent mastocytosis and succumbed to septic shock. Conclusions: This first reported case of SM-AML with KIT p.Asp419del highlights the need for comprehensive molecular testing and tailored therapy in atypical presentations.Keywords
This publication has 13 references indexed in Scilit:
- Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid LeukemiaClinical Lymphoma Myeloma and Leukemia, 2022
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalHemaSphere, 2021
- Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomesExperimental and Molecular Pathology, 2019
- Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid LeukemiaHematology/Oncology and Stem Cell Therapy, 2017
- Tyrosine kinase inhibitors in the treatment of systemic mastocytosisLeukemia Research, 2011
- Novel Germline Mutation of KIT Associated With Familial Gastrointestinal Stromal Tumors and MastocytosisGastroenterology, 2005
- AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to GleevecProceedings of the National Academy of Sciences, 2005
- Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemiasBritish Journal of Haematology, 2003